Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans

Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rat...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacologia Vol. 143; no. 4; pp. 365 - 372
Main Authors Vollenweider, F. X., Remensberger, S., Hell, D., Geyer, M. A.
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.04.1999
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0033-3158
1432-2072
DOI10.1007/s002130050960

Cover

Abstract Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.
AbstractList Rationale: Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. Objective: In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. Methods: Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. Results: As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. Conclusions: This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.
Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.
Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers.RATIONALEPrepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers.In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies.OBJECTIVEIn this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies.Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA.METHODSRats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA.As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects.RESULTSAs expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects.This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.CONCLUSIONSThis surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.
Author Hell, D.
Remensberger, S.
Geyer, M. A.
Vollenweider, F. X.
Author_xml – sequence: 1
  givenname: F. X.
  surname: Vollenweider
  fullname: Vollenweider, F. X.
– sequence: 2
  givenname: S.
  surname: Remensberger
  fullname: Remensberger, S.
– sequence: 3
  givenname: D.
  surname: Hell
  fullname: Hell, D.
– sequence: 4
  givenname: M. A.
  surname: Geyer
  fullname: Geyer, M. A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1770450$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10367553$$D View this record in MEDLINE/PubMed
BookMark eNp10VFrFDEQB_AgFXutPvoqAYtUcHWys0l2H0u1KrT0RZ-XXHa2l7KbXJOseN_elJ6oBQMhBH75M5k5Ygc-eGLspYD3AkB_SAC1QAAJnYInbCUarKsadH3AVgCIFQrZHrKjlG6hrKZtnrFDAai0lLhid9fbbUguE6dxJJsTDyPHd001U97sJvI0uPBzd38z83ZD2czOEz-9-nh19pYHzxP5FKKbQw6R35js_A13nkdTon5QTEviGzJTCeObZTY-PWdPRzMlerE_j9n3i0_fzr9Ul9efv56fXVYWG5UrJa2yoOpWkmq0RLkesJW2xUZrJKEloQSzHrpuUGTEKDsa10KQGiwilX3M3jzkbmO4WyjlfnbJ0jQZT2FJveraGhqlC3z9CN6GJfpSW49C6BZRoSjq1V4t65mGflv-bOKu_93KAk72wCRrpjEab13647SGRkJh1QOzMaQUafwrqb-faP_PRIvHR966XNocfI7GTf959QtVNqHw
CODEN PSYPAG
CitedBy_id crossref_primary_10_1080_16066350290001704
crossref_primary_10_1177_026988110201600101
crossref_primary_10_1080_02791072_2002_10399952
crossref_primary_10_1080_02791072_2002_10399951
crossref_primary_10_1177_0269881118822156
crossref_primary_10_1016_j_euroneuro_2012_09_005
crossref_primary_10_1038_sj_npp_1300396
crossref_primary_10_1093_schbul_sbn156
crossref_primary_10_1177_0269881105053287
crossref_primary_10_1038_sj_npp_1301324
crossref_primary_10_1371_journal_pone_0258849
crossref_primary_10_1007_s00213_005_0056_x
crossref_primary_10_1016_S0028_3908_03_00073_X
crossref_primary_10_1016_j_biopsych_2010_08_003
crossref_primary_10_1016_j_euroneuro_2015_12_025
crossref_primary_10_1007_s00213_007_0843_7
crossref_primary_10_1176_appi_ajp_158_10_1687
crossref_primary_10_3389_fpsyt_2017_00232
crossref_primary_10_1016_j_neuro_2024_06_014
crossref_primary_10_1017_S1461145707008322
crossref_primary_10_1038_sj_npp_1301350
crossref_primary_10_3389_fpsyt_2018_00144
crossref_primary_10_1007_s00213_009_1545_0
crossref_primary_10_1080_02791072_2001_10400568
crossref_primary_10_1038_sj_npp_1301556
crossref_primary_10_1177_155005940703800207
crossref_primary_10_31887_DCNS_2001_3_4_fxvollenweider
crossref_primary_10_1024_1016_264X_19_3_139
crossref_primary_10_1177_0269881104042615
crossref_primary_10_1177_0269881107077734
crossref_primary_10_1007_s00213_009_1635_z
crossref_primary_10_1523_JNEUROSCI_2502_11_2011
crossref_primary_10_1371_journal_pone_0078386
crossref_primary_10_1111_bph_12628
crossref_primary_10_1177_0269881106063271
crossref_primary_10_1038_sj_mp_4001159
crossref_primary_10_1097_00008877_200503000_00009
crossref_primary_10_1177_0269881116650408
crossref_primary_10_1016_j_pharmthera_2009_02_004
crossref_primary_10_1016_j_bbr_2004_04_014
crossref_primary_10_1177_026988110001400308
crossref_primary_10_1146_annurev_clinpsy_121208_131220
crossref_primary_10_1016_j_biopsych_2004_02_030
crossref_primary_10_1007_s00213_008_1072_4
crossref_primary_10_1097_00008877_200006000_00002
crossref_primary_10_1017_S1461145711000101
crossref_primary_10_1007_s00406_007_0753_z
crossref_primary_10_1177_0269881108094650
crossref_primary_10_1016_j_pbb_2010_12_011
crossref_primary_10_1017_S1461145709000480
crossref_primary_10_1124_pr_55_3_3
crossref_primary_10_1016_j_heares_2015_11_014
crossref_primary_10_1038_sj_npp_1300086
crossref_primary_10_1016_j_neubiorev_2006_09_009
crossref_primary_10_1016_j_pnpbp_2023_110843
crossref_primary_10_1007_s00213_007_0762_7
crossref_primary_10_1016_j_schres_2018_03_037
crossref_primary_10_1097_00008877_200102000_00005
crossref_primary_10_1038_sj_npp_1301009
crossref_primary_10_1016_S0149_7634_03_00031_9
crossref_primary_10_1016_S0163_7258_03_00003_2
crossref_primary_10_1038_npp_2011_228
crossref_primary_10_1016_S0278_5846_03_00081_2
crossref_primary_10_1016_j_neuropharm_2006_11_006
ContentType Journal Article
Copyright 1999 INIST-CNRS
Springer-Verlag Berlin Heidelberg 1999.
Copyright_xml – notice: 1999 INIST-CNRS
– notice: Springer-Verlag Berlin Heidelberg 1999.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1007/s002130050960
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Psychology Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Psychology
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-2072
EndPage 372
ExternalDocumentID 10367553
1770450
10_1007_s002130050960
Genre Controlled Clinical Trial
Research Support, U.S. Gov't, P.H.S
Comparative Study
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NIMH NIH HHS
  grantid: MH01228
– fundername: NIDA NIH HHS
  grantid: DA02925
GroupedDBID 40D
40E
95.
95~
AAYXX
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CITATION
RHV
SBY
SOJ
~EX
.55
3SX
IQODW
KOW
N2Q
R9-
X7M
-4W
-BR
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GNUQQ
K9.
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
ID FETCH-LOGICAL-c346t-65c6c06285e647535bd385c834773e175e350abd99d6ea1f59efb11e6dc33ec33
IEDL.DBID 7X7
ISSN 0033-3158
IngestDate Fri Jul 11 09:59:57 EDT 2025
Sat Aug 16 19:52:16 EDT 2025
Sat Sep 28 08:38:24 EDT 2024
Wed Apr 02 07:26:03 EDT 2025
Tue Jul 01 04:11:30 EDT 2025
Thu Apr 24 22:56:00 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Amphetamine derivatives
Human
Sensory filter
Healthy subject
Rat
Serotonin
Toxicity
Interspecific comparison
Rodentia
Oral administration
Startle reflex
Vertebrata
Mammalia
Acoustic stimulus
Animal
Double blind study
Subcutaneous administration
Drug of abuse
Gating
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c346t-65c6c06285e647535bd385c834773e175e350abd99d6ea1f59efb11e6dc33ec33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 10367553
PQID 3117833631
PQPubID 47309
PageCount 8
ParticipantIDs proquest_miscellaneous_69820467
proquest_journals_3117833631
pubmed_primary_10367553
pascalfrancis_primary_1770450
crossref_primary_10_1007_s002130050960
crossref_citationtrail_10_1007_s002130050960
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-04-01
PublicationDateYYYYMMDD 1999-04-01
PublicationDate_xml – month: 04
  year: 1999
  text: 1999-04-01
  day: 01
PublicationDecade 1990
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacologia
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 1999
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
SSID ssj0000484
ssj0068394
Score 1.9007274
Snippet Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus....
Rationale: Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 365
SubjectTerms Acoustic Stimulation
Adult
Affect - drug effects
Analysis of Variance
Animals
Biological and medical sciences
Blindness
Dose-Response Relationship, Drug
Double-Blind Method
Drug addictions
Drug development
Drug dosages
Ecstasy
Habituation, Psychophysiologic - drug effects
Humans
Laboratory animals
MDMA
Medical sciences
Mental disorders
Middle Aged
N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage
N-Methyl-3,4-methylenedioxyamphetamine - pharmacology
Placebos
Psychometrics
Rats
Rats, Sprague-Dawley
Reflex, Startle - drug effects
Schizophrenia
Sensorimotor gating
Serotonin
Serotonin Agents - administration & dosage
Serotonin Agents - pharmacology
Startle response
Toxicology
Title Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans
URI https://www.ncbi.nlm.nih.gov/pubmed/10367553
https://www.proquest.com/docview/3117833631
https://www.proquest.com/docview/69820467
Volume 143
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1432-2072
  dateEnd: 20240929
  omitProxy: true
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: ABDBF
  dateStart: 19961001
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1432-2072
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1432-2072
  dateEnd: 20171231
  omitProxy: true
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: 7X7
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1432-2072
  dateEnd: 20171231
  omitProxy: true
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: BENPR
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1432-2072
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1432-2072
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000484
  issn: 0033-3158
  databaseCode: U2A
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MwxtZ9NOvH9DDCBjGNqg_bTyPZGsogWRgt5M3I8nkUWjutEpj_-54sJW4fugdjhIRsdCfdT9Ld7wj5IhMoY1YIlIBMI6FTESFuNpFxHhjJUEHZRshNZ-r8UvxayEU4cLPBrXKzJrYLdVEbd0Z-whmLE84VZ9-Xt5HLGuVuV0MKjedklyFUcVodL-JuJRYuCNMXFCIBT8nMXUCZTALhZhtH5ywd91Qow0cG6tVSWxyr0ie5eBqFttZo8oa8DjCSjrzc35JnUO2RF9NwUb5H-nNPSd0M6EUXYWUHtE_nHVl1847c_l62fltAg2cHrUvKByJyqaUbNEnYZf2vcSWNgoeVvsEP0K_Tn9PRN1pX1OI-GMcJJV7fUUfXUf2lVxVFxbLUuXysLfWxlg1t8wHa9-Rycnbx4zwKaRgiw4VaRUoaZdpQS1ACdzcyL3giTcJFHHNA-AFcDnVepGmhQLNSplDmjIEqDOeAzweyU9UV7BMKuRyW4Cj0i1xozXKRqtMyzk-BJYkyvEcGm7HPTOAod6kyrrMtu_JDUfVIf9t86ck5nmp49EiQXes4RkyL9YcbwWZhDtus07ge-bytxtnnrlR0BfXaZipFBIW2pkc-enV48B8c92KSf_p_1wfkpSeCcL5Ah2RndbeGI4Q5q_y41eVjsjuajMczfI_PZvM_909T-0M
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRQIkVEF5pQ-6B4hAioWdfdg-IFRRqpTWpYdUys2112OEBHZaJ6L-U_xGZr123B7KrcfVrmzLM5751jvfNwBvZYC572WCLCBDRyShcAg3a0ebCozAVZg3DLnoVE3OxbeZnK3B344LY8oqu5jYBOqs1OYf-UfueX7AueLe5_mlY7pGmdPVroWGdYtjrP_Qlq36dHRA9n03Hh9-nX6ZOG1XAUdzoRaOklrphjmIShBYl2nGA6kDLnyfI2VT5NJN0iwMM4WJl8sQ89TzUGWac9TmByiF_AeCu8Jo9fszv4_8wpA-7UAR8rAS0NwQ2GTQCnw2vD2TWbmVXnFvJcQn86Qi2-S2qcbdqLfJfodPYaOFrWzf-tkzWMNiEx5G7cH8JgzPrAR2PWLTntFVjdiQnfXi2PVzuPw-b-rEkLWVJKzMGR8Jx7SyrikF0iXL69qMEnI0XCS_6QbsfXQQ7X9gZcEq2neTXcjDyitm5EGKH-xnwciRK2ZKTJYVs9zOmjX9B6sXcH4vBnoJ60VZ4GtgmEo3RyPZn6UiSbxUhGqc--kYvSBQmg9g1L37WLea6KY1x694peZ801QDGK6Wz60YyF0Ld28Zsl_t-4ShaX6nM2zcxowq7j18AHurafrazRFOUmC5rGIVEmKj3DaAV9YdbjwHp72f5Fv_v_QePJpMo5P45Oj0eBseWxEKU4e0A-uLqyXuEsRapG8av2Zwcd8f0j9gRDSk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9NAEB1VRaqQUAXlo4GW7gEikGI1zn7ZB4QqQtRSUnJopdyMvR4jpGKndSLwX-PXMeu14_ZQbj2udrW2_GZ3Zr1v3gC8kQFm2k8FISBDT8Sh8ChuNp6xDIxgqDCrM-SmZ-r4QnyZy_kG_G1zYSytst0T6406LYz9R37IfV8HnCvuH2YNLWI2nnxcXHm2gpS9aW3LaTgTOcXqNx3fyg8nY8L67Wg0-Xz-6dhrKgx4hgu19JQ0ytRZhKgEBe4ySXkgTcCF1hzJsyKXwzhJwzBVGPuZDDFLfB9VajhHY3-G0vb_QHPBLZ1Mz3XnBYRNAHUNRVGIk4PmNplNBo3YZ53DZ70sdzIsw1vO8dEiLgmnzBXYuDsCrj3h5DFsNyEsO3I29wQ2MN-BrWlzSb8D_ZmTw64G7LzL7ioHrM9mnVB29RSuvi1qzhiyhlXCiozxgfBsWeuK3CFNWfypbCsmo8Nl_IsewN5Nx9Oj96zIWUlncMKFrK24ZlYqJP_BfuaMjLpklm6yKpnL86xYXYuwfAYX9wLQc9jMixx3gWEihxla-f40EXHsJyJUo0wnI_SDQBneg0H77SPT6KPbMh2X0VrZ-SZUPeivhy-cMMhdA_dvAdmN1priaerfa4GNmv2jjDpr78HBuptWvr3OiXMsVmWkQoreyM_14IUzhxvvwekcKPnL_099AFu0hKKvJ2enr-Ch06OwlKQ92Fxer3Cfoq1l8ro2awbf73sd_QPmwDjf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opposite+effects+of+3%2C4-methylenedioxymethamphetamine+%28MDMA%29+on+sensorimotor+gating+in+rats+versus+healthy+humans&rft.jtitle=Psychopharmacology&rft.au=Vollenweider%2C+F.+X&rft.au=Remensberger%2C+S&rft.au=Hell%2C+D&rft.au=Geyer%2C+M.+A&rft.date=1999-04-01&rft.pub=Springer+Nature+B.V&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=143&rft.issue=4&rft.spage=365&rft.epage=372&rft_id=info:doi/10.1007%2Fs002130050960&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon